GKB Ophthalmics DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY23Mar 2023

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
	0.95×
	0.84×
	−13.1%
	0.56×
	1.79×
	−10.4%
	−10.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

GKB₹59.68

GKB Ophthalmics Limited

· Pharma & Health

₹ CrorePeersFABTECH LAXMIDENTL TARSONS FISCHERMcap ₹30.1 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

	Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023
	5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
	Tax Burden (Net Income/Pretax) ×	0.95
	Interest Burden (Pretax/EBIT) ×	0.84
	EBIT Margin %	-13.10
	Asset Turnover ×	0.56
	Financial Leverage (Assets/Equity) ×	1.79
	ROE (5-step product, year-end total equity) %	-10.39
	ROE (owners' profit / average owners' equity) %	-10.47

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.